- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Acorda Therapeutics Inc. (ACOR)
by latest | most commented
-
Dealmaking Sweeps the Biotech Sector
-
FDA Calendar Updates: Repros, Discovery, Acorda, Human Genome Sciences
-
Preview from Europe: Stocks Jump Out of the Gate Before Fading
-
30 Possible Pandemic Profit Plays: Bullish Biotech and Drug Stocks to Watch
-
Bullish on Acorda: New Drug Looks Promising
-
Monday Options Update: KMB, S, EEM, XLU, UAUA & ACOR
-
Q1 2009 Biotech Earnings Roundup: The Good, the Bad, and the Ugly
-
Acorda Pops on Good News
-
FDA Calendar Updates: Acorda, Roche
-
Why I Doubt the FDA Will Approve Acorda's Fampridine
-
Thursday's Pre-Market Report:
-
FDA, Clinical Trial Calendar Updates: Acorda, Alkermes, GTx
-
Q1 2009 Biotech Roundup: The Good, the Bad and the Ugly
-
FDA and Clinical Trial Updates: Weight Loss, Diabetes and More
-
Tuesday's Options Recap
-
Acorda Down on FDA Delay
-
Where Might Genentech Investors Redeploy $47B?
-
Behind the Acorda Rumors
-
Wall Street Breakfast: Must-Know News
-
FDA Decisions and Clinical Trials: An Updated Calendar
-
Monday Options Update: EWJ, XLF, ACOR, TWC & GE
-
SAC Capital Portfolio Update: 37 13G Filings
-
20 Emerging Healthcare Stocks to Watch in '09
-
9 Possible Pharma Deals for 2009
-
A Biotech Bloom in July
-
MS Drug Fampridine Sends Acorda Stock Way Up
-
Icahn's Hedge Fund Has New Stakes In Genzyme and Childrens Place, Among Others
-
Acorda Therapeutics: Sell or Short?
-
Loeb's Third Point Issues Latest 13F: Summary of Holdings
-
Loeb's Third Point LLC Lowering Its Stake in Acorda
-
Biotech Week in Review: Holding Steady
-
Activist Hedge Fund Seeks Sale of Acorda
-
Acorda Therapeutics Responds to Loeb's Sale Suggestion
-
Acorda Therapeutics: Loeb's Third Point Urges Sale of Company
-
Eye on Acorda Therapeutics
-
2007: The Year Of Biotech IPOs?
-
Acorda Proves That Biotech Investing is Volatile, Unpredictable and Dangerous